The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, with a median survival time of 10-12 months. Clinically, these poor outcomes are attributed to several factors, including late stage at the time of diagnosis impeding resectability, as well as multi-drug resistance. Despite the high pre...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Front Oncol
Glavni autori: Principe, Daniel R., Underwood, Patrick W., Korc, Murray, Trevino, Jose G., Munshi, Hidayatullah G., Rana, Ajay
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2021
Teme:
Oncology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8319847/
https://ncbi.nlm.nih.gov/pubmed/34336673
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.688377
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items